NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT02402062 2020-07-27
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01215578 2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT00397787 2013-06-04
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
National Cancer Institute (NCI)
Phase 2 Completed
NCT00967603 2012-02-01
PACT-12
IRCCS San Raffaele
Phase 2 Completed
NCT00673504 2011-12-01
First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer
Central European Society for Anticancer Drug Research
Phase 2 Completed